Distribution and Prognostic Significance of Estrogen Receptor α (ERα), Estrogen Receptor β (ERβ), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma.
{"title":"Distribution and Prognostic Significance of Estrogen Receptor <i>α</i> (ER<i>α</i>), Estrogen Receptor <i>β</i> (ER<i>β</i>), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma.","authors":"Anjali Mishra, Niraj Kumari, Chandan Kumar Jha, Raouef Ahamed Bichoo, Shravan Kumar Mishra, Narendra Krishnani, Saroj Kanta Mishra","doi":"10.1155/2020/6935724","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The primary aim of this study was to determine the incidence of estrogen receptor <i>α</i> (ER<i>α</i>), estrogen receptor <i>β</i> (ER<i>β</i>), and human epidermal growth factor receptor 2 (HER-2) expression in various subtypes of thyroid carcinoma (TC) of follicular origin and the secondary aim was to correlate the expression with various clinicopathologic prognostic factors.</p><p><strong>Methods: </strong>Immunohistochemistry analysis was performed on archival paraffin-embedded tissue sections (1991-2016). ER<i>α</i>, ER<i>β,</i> and HER-2 expressions were correlated with clinicopathologic prognostic factors, disease recurrence, and overall survival (OS).</p><p><strong>Results: </strong>A total of 264 TC patients were included in the study. Incidences of ER<i>α</i>, ER<i>β,</i> and HER-2 were 8.1 vs 16.3 vs 13.9% (<i>p</i>=0.15), 26.6 vs 11.5 vs 36.1% (<i>p</i>=0.002), and 12.9 vs 2.9 vs 0% (<i>p</i>=0.003) in papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and poorly differentiated thyroid carcinoma (PDTC), respectively. Overall ER<i>α</i> had significant correlation with distant metastases (0.038) and in case of PDTC with multicentricity (<i>p</i>=0.037). ER<i>β</i> had significant correlation with lymph node metastases (<i>p</i>=0.023) in FTC. HER-2 correlated with tumor size (<i>p</i>=0.027) only on univariate analysis. OS did not correlate with expression of any receptor.</p><p><strong>Conclusion: </strong>ER<i>α</i>, ER<i>β,</i> and HER-2 have differential expression and prognostic implications in different TC subtypes.</p>","PeriodicalId":17394,"journal":{"name":"Journal of Thyroid Research","volume":"2020 ","pages":"6935724"},"PeriodicalIF":1.7000,"publicationDate":"2020-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/6935724","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thyroid Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/6935724","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 5
Abstract
Purpose: The primary aim of this study was to determine the incidence of estrogen receptor α (ERα), estrogen receptor β (ERβ), and human epidermal growth factor receptor 2 (HER-2) expression in various subtypes of thyroid carcinoma (TC) of follicular origin and the secondary aim was to correlate the expression with various clinicopathologic prognostic factors.
Methods: Immunohistochemistry analysis was performed on archival paraffin-embedded tissue sections (1991-2016). ERα, ERβ, and HER-2 expressions were correlated with clinicopathologic prognostic factors, disease recurrence, and overall survival (OS).
Results: A total of 264 TC patients were included in the study. Incidences of ERα, ERβ, and HER-2 were 8.1 vs 16.3 vs 13.9% (p=0.15), 26.6 vs 11.5 vs 36.1% (p=0.002), and 12.9 vs 2.9 vs 0% (p=0.003) in papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and poorly differentiated thyroid carcinoma (PDTC), respectively. Overall ERα had significant correlation with distant metastases (0.038) and in case of PDTC with multicentricity (p=0.037). ERβ had significant correlation with lymph node metastases (p=0.023) in FTC. HER-2 correlated with tumor size (p=0.027) only on univariate analysis. OS did not correlate with expression of any receptor.
Conclusion: ERα, ERβ, and HER-2 have differential expression and prognostic implications in different TC subtypes.
目的:本研究的主要目的是确定雌激素受体α (ERα)、雌激素受体β (ERβ)和人表皮生长因子受体2 (HER-2)在不同亚型滤泡源性甲状腺癌(TC)中的表达情况，次要目的是探讨其表达与各种临床病理预后因素的相关性。方法:对1991-2016年档案石蜡包埋组织切片进行免疫组化分析。ERα、ERβ和HER-2的表达与临床病理预后因素、疾病复发和总生存期(OS)相关。结果:共纳入264例TC患者。在甲状腺乳头状癌(PTC)、滤泡性甲状腺癌(FTC)和低分化甲状腺癌(PDTC)中，ERα、ERβ和HER-2的发生率分别为8.1 vs 16.3 vs 13.9% (p=0.15)、26.6 vs 11.5 vs 36.1% (p=0.002)和12.9 vs 2.9 vs 0% (p=0.003)。总体ERα与远处转移(0.038)和多中心性PDTC (p=0.037)有显著相关性。ERβ与FTC患者淋巴结转移有显著相关性(p=0.023)。HER-2仅在单因素分析中与肿瘤大小相关(p=0.027)。OS与任何受体的表达均无相关性。结论:ERα、ERβ、HER-2在不同TC亚型中表达差异及预后意义。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
